search
Back to results

Open and Comparative Study to Measure Tolerability and Efficacy of Taro Elixir (E01GOU-INH0109)

Primary Purpose

Acne Vulgaris II or III Degree, Boils

Status
Unknown status
Phase
Phase 3
Locations
Brazil
Study Type
Interventional
Intervention
oxytetracycline, taro elixir
Taro Elixir
Sponsored by
Laboratorios Goulart S.A.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acne Vulgaris II or III Degree focused on measuring Acne Vulgaris, Boil, Taro Elixir

Eligibility Criteria

14 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Both of gender patient, older than 14 years;
  • Patient with boils or acne vulgaris II or III degree;
  • The score must be at least than 4, for 2 or more question of VAS (visual analog scale);
  • Patient that have been used an effective contraceptive method in the last 3 months, including sexual abstinence and that keep using that method during the study until a month after;
  • Patient that have been accepted to participate of the study and signed the Informed Consent or in case of younger than 18 years, the responsable must read and sign the Informed Consent.
  • Patient that have been accepted to meet all the visits stipulated at the protocol, whenever the investigator request in .

Exclusion Criteria:

  • Patient of female gender that has been pregnant, breastfeeding or that has not been use a safe contraceptive method (oral contraceptives or barrier methods). Sexual abstinence will be accept if the investigator think that it is relevant.
  • Patient that has been use antiandrogens (cyproterone, finasteride, flutamide, tamoxifen, spironolactone);
  • Patient with acne I or IV degree;
  • Patient that has been receive some treatment for acne as antibiotics, corticosteroid or any medicine that can maybe interfere in the study results: a month for systemic treatment or two weeks for topic treatment, before inclusion or during the study;
  • Patient that received treatment with oral retinoids within 6 months before the inclusion and during the study;
  • Patient that had a known decompensated diabetes history;
  • Patient with immunodeficiency and liver, renal, cardiac, digestive, metabolic, endocrinological, hematological, neurological or psychiatric disorders, evaluated through anamnesis by the investigator, tha can maybe interfere on the study evaluation. Even the patient with facial dermatoses such as psoriasis, acne rosacea, allergic dermatitis, skin infections caused by fungi, bacteria and viruses;
  • Patient with alcoholism history, illicit drugs use, psychological ou emotional problems that can maybe void the Informed Consent or limit the capacity of the patient follow the protocol requirements ;
  • Patient hypersensitive to any one of the medicine components;
  • Patient that have been used any drug under search, 3 months before the visit number one.

Sites / Locations

  • Policlínica de Mogi das Cruzes
  • Faculdade de Medicina do ABC
  • Alergoclínica - Centro de alergia e dermatologia
  • Alergoclínica - Centro de alergia e dermatologia

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

oxytetracycline

Taro Elixir

Arm Description

Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.

Outcomes

Primary Outcome Measures

Measure the efficacy in the treatment of boils or acne vulgaris II and III degree with taro elixir compared with Oxytetracycline.

Secondary Outcome Measures

Measure the tolerability in the treatment evolution of boils or acne vulgaris II and III with taro elixir compare with Oxytetracycline.

Full Information

First Posted
December 14, 2009
Last Updated
March 18, 2010
Sponsor
Laboratorios Goulart S.A.
search

1. Study Identification

Unique Protocol Identification Number
NCT01032499
Brief Title
Open and Comparative Study to Measure Tolerability and Efficacy of Taro Elixir
Acronym
E01GOU-INH0109
Official Title
Multicenter Clinical Study,Phase III, Prospective, Randomized, Open and Comparative to Measure Tolerability and Efficacy of Taro Elixir on the Evolution Treatment of Acne Vulgaris II and III Degree or of Furunculosis Compared With Oxytetracycline
Study Type
Interventional

2. Study Status

Record Verification Date
December 2009
Overall Recruitment Status
Unknown status
Study Start Date
May 2010 (undefined)
Primary Completion Date
July 2010 (Anticipated)
Study Completion Date
October 2010 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
Laboratorios Goulart S.A.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To measure the efficacy of Taro Elixir compare with Oxytetracycline in the treatment of boils or acne.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acne Vulgaris II or III Degree, Boils
Keywords
Acne Vulgaris, Boil, Taro Elixir

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
oxytetracycline
Arm Type
Active Comparator
Arm Title
Taro Elixir
Arm Type
Experimental
Arm Description
Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
Intervention Type
Drug
Intervention Name(s)
oxytetracycline, taro elixir
Intervention Description
comparison of treatment efficacy between oxytetracycline and taro elixir
Intervention Type
Drug
Intervention Name(s)
Taro Elixir
Intervention Description
Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
Primary Outcome Measure Information:
Title
Measure the efficacy in the treatment of boils or acne vulgaris II and III degree with taro elixir compared with Oxytetracycline.
Time Frame
90 days
Secondary Outcome Measure Information:
Title
Measure the tolerability in the treatment evolution of boils or acne vulgaris II and III with taro elixir compare with Oxytetracycline.
Time Frame
90 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
14 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Both of gender patient, older than 14 years; Patient with boils or acne vulgaris II or III degree; The score must be at least than 4, for 2 or more question of VAS (visual analog scale); Patient that have been used an effective contraceptive method in the last 3 months, including sexual abstinence and that keep using that method during the study until a month after; Patient that have been accepted to participate of the study and signed the Informed Consent or in case of younger than 18 years, the responsable must read and sign the Informed Consent. Patient that have been accepted to meet all the visits stipulated at the protocol, whenever the investigator request in . Exclusion Criteria: Patient of female gender that has been pregnant, breastfeeding or that has not been use a safe contraceptive method (oral contraceptives or barrier methods). Sexual abstinence will be accept if the investigator think that it is relevant. Patient that has been use antiandrogens (cyproterone, finasteride, flutamide, tamoxifen, spironolactone); Patient with acne I or IV degree; Patient that has been receive some treatment for acne as antibiotics, corticosteroid or any medicine that can maybe interfere in the study results: a month for systemic treatment or two weeks for topic treatment, before inclusion or during the study; Patient that received treatment with oral retinoids within 6 months before the inclusion and during the study; Patient that had a known decompensated diabetes history; Patient with immunodeficiency and liver, renal, cardiac, digestive, metabolic, endocrinological, hematological, neurological or psychiatric disorders, evaluated through anamnesis by the investigator, tha can maybe interfere on the study evaluation. Even the patient with facial dermatoses such as psoriasis, acne rosacea, allergic dermatitis, skin infections caused by fungi, bacteria and viruses; Patient with alcoholism history, illicit drugs use, psychological ou emotional problems that can maybe void the Informed Consent or limit the capacity of the patient follow the protocol requirements ; Patient hypersensitive to any one of the medicine components; Patient that have been used any drug under search, 3 months before the visit number one.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Carlos Machado
Phone
+55 11 4993-5400
Email
dermatologia@fmabc.br
First Name & Middle Initial & Last Name or Official Title & Degree
Selma Squassoni
Phone
+55 11 49935459
Email
selma_denis@yahoo.com.br
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carlos Machado
Organizational Affiliation
Faculdade de Medicina do ABC
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Andrea Gerbase
Organizational Affiliation
Alergoclínica - Centro de Alergia e dermatologia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Denise Steiner
Organizational Affiliation
Policlínica Mogi das Cruzes
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jussara Marin
Organizational Affiliation
Alergoclínica - Centro de alergia e dermatologia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Policlínica de Mogi das Cruzes
City
Mogi das Cruzes
State/Province
São Paulo
ZIP/Postal Code
08780070
Country
Brazil
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Denise Steiner
Phone
+55 11 4728-5383
Email
steiner@uol.com.br
First Name & Middle Initial & Last Name & Degree
Denise Steiner
Facility Name
Faculdade de Medicina do ABC
City
Santo André
State/Province
São Paulo
ZIP/Postal Code
09060650
Country
Brazil
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carlos Machado
Phone
+55 11 4993-5400
Email
dermatologia@fmabc.br
First Name & Middle Initial & Last Name & Degree
Selma Squassoni
Phone
+55 11 49935459
Email
selma_denis@yahoo.com.br
First Name & Middle Initial & Last Name & Degree
Carlos Machado
Facility Name
Alergoclínica - Centro de alergia e dermatologia
City
São Paulo
ZIP/Postal Code
03066030
Country
Brazil
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jussara Marin
Phone
+55 11 2942-1833
Email
jmarin@alergoclinica.com.br
First Name & Middle Initial & Last Name & Degree
Jussara Marin
Facility Name
Alergoclínica - Centro de alergia e dermatologia
City
São Paulo
ZIP/Postal Code
04505000
Country
Brazil
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrea Gerbase
Phone
+55 11 5682-8711
Email
andrea.gerbase@alergoclinica.com.br
First Name & Middle Initial & Last Name & Degree
Andrea Gerbase

12. IPD Sharing Statement

Learn more about this trial

Open and Comparative Study to Measure Tolerability and Efficacy of Taro Elixir

We'll reach out to this number within 24 hrs